Terms: = Squamous Cell Carcinoma AND BRAF, MGC126806, 673, ENSG00000157764, MGC138284, RAFB1, P15056, B-raf 1, BRAF1, B-raf1 AND Clinical Outcome
11 results:
1. Comprehensive molecular analysis of driver mutations in non-small cell lung carcinomas and its correlation with PD-L1 expression, An Indian perspective.
Aggarwal A; Sharma S; Brar Z; Kumar V; Kumar A; Katara R; Mohanty SK
Pathol Res Pract; 2024 Jan; 253():155013. PubMed ID: 38096714
[TBL] [Abstract] [Full Text] [Related]
2. Significance of druggable targets (PD-L1, KRAS, braf, PIK3CA, MSI, and HPV) on curatively resected esophageal squamous cell carcinoma.
Lee HK; Kwon MJ; Ra YJ; Lee HS; Kim HS; Nam ES; Cho SJ; Park HR; Min SK; Seo J; Choe JY; Min KW; Kang SY
Diagn Pathol; 2020 Oct; 15(1):126. PubMed ID: 33054840
[TBL] [Abstract] [Full Text] [Related]
3. clinical outcome of stereotactic body radiotherapy for lung-only oligometastatic head and neck squamous cell carcinoma: Is the deferral of systemic therapy a potential goal?
Bonomo P; Greto D; Desideri I; Loi M; Di Cataldo V; Orlandi E; Iacovelli NA; Becherini C; Visani L; Salvestrini V; Mariotti M; Livi L
Oral Oncol; 2019 Jun; 93():1-7. PubMed ID: 31109688
[TBL] [Abstract] [Full Text] [Related]
4. Long-term clinical benefit from salvage EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer patients with EGFR wild-type tumors.
Koinis F; Voutsina A; Kalikaki A; Koutsopoulos A; Lagoudaki E; Tsakalaki E; Dermitzaki EK; Kontopodis E; Pallis AG; Georgoulias V; Kotsakis A
Clin Transl Oncol; 2018 Feb; 20(2):140-149. PubMed ID: 28631135
[TBL] [Abstract] [Full Text] [Related]
5. squamous cell carcinoma and keratoacanthomas are biologically distinct and can be diagnosed by light microscopy: a review.
Selmer J; Skov T; Spelman L; Weedon D
Histopathology; 2016 Oct; 69(4):535-41. PubMed ID: 27323251
[TBL] [Abstract] [Full Text] [Related]
6. Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma.
Yang CY; Lin MW; Chang YL; Wu CT; Yang PC
Eur J Cancer; 2016 Apr; 57():91-103. PubMed ID: 26901614
[TBL] [Abstract] [Full Text] [Related]
7. Significance of EGFR signaling pathway genetic alterations in radically resected non-small cell lung cancers from a Polish cohort. One institutional study.
Kowalczuk O; Kozlowski M; Milewski R; Minarowski L; Reszec J
Adv Med Sci; 2015 Sep; 60(2):277-86. PubMed ID: 26118982
[TBL] [Abstract] [Full Text] [Related]
8. Molecular Characteristics of Basaloid squamous cell carcinoma of the Esophagus: Analysis of KRAS, braf, and PIK3CA Mutations and LINE-1 Methylation.
Baba Y; Ishimoto T; Harada K; Kosumi K; Murata A; Miyake K; Hiyoshi Y; Kurashige J; Iwatsuki M; Iwagami S; Miyamoto Y; Sakamoto Y; Yoshida N; Oki E; Iyama K; Watanabe M; Baba H
Ann Surg Oncol; 2015 Oct; 22(11):3659-65. PubMed ID: 25691283
[TBL] [Abstract] [Full Text] [Related]
9. Primary squamous cell carcinoma of the endometrium: clinicopathologic and molecular characteristics.
Bures N; Nelson G; Duan Q; Magliocco A; Demetrick D; Duggan MA
Int J Gynecol Pathol; 2013 Nov; 32(6):566-75. PubMed ID: 24071873
[TBL] [Abstract] [Full Text] [Related]
10. Phase II trial (BREAK-2) of the braf inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma.
Ascierto PA; Minor D; Ribas A; Lebbe C; O'Hagan A; Arya N; Guckert M; Schadendorf D; Kefford RF; Grob JJ; Hamid O; Amaravadi R; Simeone E; Wilhelm T; Kim KB; Long GV; Martin AM; Mazumdar J; Goodman VL; Trefzer U
J Clin Oncol; 2013 Sep; 31(26):3205-11. PubMed ID: 23918947
[TBL] [Abstract] [Full Text] [Related]
11. Human papillomavirus and gene mutations in head and neck squamous carcinomas.
Friedland P; Thomas A; Naran A; Amanuel B; Grieu-Iacopetta F; Carrello A; Harnett G; Meyer C; Phillips M
ANZ J Surg; 2012 May; 82(5):362-6. PubMed ID: 22507644
[TBL] [Abstract] [Full Text] [Related]
